Ispecimen Inc. cash flow statement
In fiscal 2025, Ispecimen Inc.'s operations generated −$4.2m of cash; it spent $454 on capital projects, leaving free cash flow of −$4.2m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −0 | −11 | −6 | −6 | −8 | −4 | −7 |
| Depreciation and amortisation | 0 | 0 | 0 | 2 | 2 | 2 | 1 |
| Stock-based pay | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −0 | −11 | −6 | −6 | −8 | −4 | −7 |
| Free cash flow after stock pay | −0 | −11 | −7 | −6 | −9 | −4 | −7 |
| Shares issued | — | 2 | — | — | 0 | 4 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −1,079 | −3,573 | −1,096 | −192 | −2,036 | −917 | −3,362 | −690 |
| Depreciation and amortisation | 17 | 548 | 433 | 17 | 17 | 408 | 136 | 2 |
| Stock-based pay | 20 | 11 | 16 | 2 | 2 | 2 | 1 | 0 |
| Capital spending | 15 | 8 | — | — | 0 | 0 | — | 0 |
| Free cash flow | −1,094 | −3,581 | — | — | −2,036 | −917 | — | −690 |
| Free cash flow after stock pay | −1,114 | −3,592 | — | — | −2,037 | −919 | — | −690 |
| Shares issued | 0 | −1,096 | — | — | 1,751 | 2,250 | — | — |
Compare with peers
- YD Bio Ltd cash flow
- Quantum-si Inc cash flow
- Aclarion, Inc. cash flow
- Bionexus Gene Lab Corp cash flow
- Seer, Inc. cash flow
Head to head: ISPC vs YDESISPC vs QSIACON vs ISPC
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies